Med Biogene Inc (TSE:MBI.H)
TSXV:MBI.H
Canadian Market
Holding TSE:MBI.H?
Track your performance easily

Med Biogene (MBI.H) Income Statement

4 Followers

Med Biogene Income Statement

Last quarter (Q2 2024), Med Biogene's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Med Biogene's net income was $-20.00K. See Med Biogene’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 56.36K$ 58.11K$ 63.06K$ 59.96K$ 54.54K$ 63.48K
Operating Income
$ -56.36K$ -58.11K$ -63.06K$ -59.96K$ -54.54K$ -63.48K
Net Non Operating Interest Income Expense
------
Other Income Expense
------
Pretax Income
$ -56.36K$ -58.11K$ -63.06K$ -59.96K$ -54.54K$ -63.48K
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -56.36K$ -58.11K$ -63.06K$ -59.96K$ -54.54K$ -63.48K
Basic EPS
----$ >-0.01$ -0.01
Diluted EPS
----$ >-0.01$ -0.01
Basic Average Shares
$ 69.03M$ 17.26M$ 17.01M$ 15.22M$ 13.26M$ 11.25M
Diluted Average Shares
$ 69.03M$ 17.26M$ 17.01M$ 17.26M$ 13.26M$ 11.25M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 56.36K$ 58.11K$ 63.06K$ -59.96K$ 54.54K$ 63.48K
Net Income From Continuing And Discontinued Operation
$ -56.36K$ -58.11K$ -63.06K$ -59.96K$ -54.54K$ -63.48K
Normalized Income
$ -49.10K$ -42.71K$ -46.35K$ -44.07K$ -54.54K$ -63.48K
Interest Expense
------
EBIT
$ -56.36K$ -58.11K$ -63.06K$ -59.96K$ -54.54K$ -63.48K
EBITDA
$ -56.36K$ -58.11K$ -63.06K$ -59.96K$ -54.54K$ -63.48K
Currency in USD

Med Biogene Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis